Table 3. The relationship between clinicopathological characteristics and ER status of patients with primary operable invasive ductal breast cancer.

	ER negative ( n =159)	ER positive ( n =283)	(P-value)
Age (⩽50/>50 years)	59/100	66/217	0.002
Size (⩽20/21–50/>50 mm)	76/78/4	190/86/7	<0.001
Grade (I/II/III)	6/25//128	80/147/56	<0.001
Involved lymph node (0/1–3/>3)	83/38/37	160/83/36	0.042
Progesterone-receptor status (PR−/PR+)	151/6	88/191	<0.001
HER-2 status (HER-2−/HER-2+)	109/47	253/26	<0.001
Ki-67 status (low Ki-67/high Ki-67)	124/32	197/72	0.149
Vascular invasion (absent/present)	49/74	140/88	<0.001
General inflammatory cell infiltrate (absent/present)	0/159	29/254	<0.001
% Tumour lymphocyte infiltrate (median, range)	95 (4–100)	98 (0–100)	<0.001
% Tumour plasma cell infiltrate (median, range)	2 (0–90)	1 (0–90)	<0.001
% Other inflammatory cell infiltrate (median, range)	1 (0–41)	0 (0–85)	<0.001
Macrophages (median, range)	145 (16–619)	116 (14–450)	0.001
Loco-regional treatment (Lumpectomy±radiotherapy/mastectomy±radiotherapy)	58/101	112/171	0.521
Systemic treatment (ER-based treatment; hormonal/hormonal+chemotherapy/chemotherapy/none)	38/23/82/13	193/61/13/13	<0.001
Cancer-specific survival (months)a	134 (123–145)	159 (153–164)	<0.001

Abbreviations: CI=confidence interval; ER=oestrogen receptor; HER-2=human epidermal growth factor receptor-2; PR=progesterone receptor.

^aMean (95% CI).